Connect to a lawyer

CNP Advised Fund Singapore a Pre-IPO investment Round of Biolidics Limited

Stay informed with all the latest news and developments at Interlaw and our strategic partners. Read all about our recent cross-border mandates, partner hires, office openings, pro bono and community activities, award wins and other achievements. For all media and press enquiries please email Imogen Lee, Interlaw's International Director of Marketing and Communications.

Interlaw's representative firm in Singapore, Colin Ng & Partners LLP (“CNP”), is advising Fund Singapore on a pre-IPO investment round of medical technology business Biolidics Limited.

The IPO is set to raise approximately S$6.1m in net proceeds, some of which will be used to develop Biolidics' clinical services applications and the customer segment of the company's products. 

The fundraising will also advance Biolidics’ pipeline of products through in-house development, investments, mergers and acquisitions, joint ventures and/or strategic collaborations. 

The CNP team acting for Fund Singapore comprised Christopher Huang (partner), Randall Perera (senior associate) and Rajkumar Mannar (associate) (all pictured above).

Biolidics, which was incorporate in 2009, successfully listed on the Catalist Board of the Singapore Exchange on 19 December 2018.